Longeveron (NASDAQ:LGVN) Releases Earnings Results

Longeveron (NASDAQ:LGVN) issued its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.01), FiscalAI reports. Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. The business had revenue of $0.29 million during the quarter, compared to the consensus estimate of $0.33 million.

Longeveron Price Performance

Shares of NASDAQ LGVN traded up $0.06 during mid-day trading on Wednesday, hitting $0.75. 835,533 shares of the stock traded hands, compared to its average volume of 2,449,461. The company has a debt-to-equity ratio of 0.05, a current ratio of 3.88 and a quick ratio of 3.88. Longeveron has a twelve month low of $0.47 and a twelve month high of $1.23. The company has a market cap of $23.36 million, a PE ratio of -0.66 and a beta of -0.31. The firm has a 50 day simple moving average of $0.71 and a two-hundred day simple moving average of $0.76.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen lowered Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. HC Wainwright lowered their target price on Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, May 4th. Weiss Ratings raised shares of Longeveron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Finally, Maxim Group cut shares of Longeveron from a “buy” rating to a “hold” rating in a research report on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.50.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new position in Longeveron stock. XTX Topco Ltd bought a new stake in Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent quarter. Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.